Dr. Nathaniel Brown MD is Chief Medical Officer at Presidio Pharmaceuticals, in San Francisco, CA, Previously he held positions as Chief Medical Officer at Idenix Pharmaceuticals, and Hepatitis Section head, at GlaxoWellcome/GlaxoSmithKline. Prior to his pharmaceutic career Dr. Brown held full-time faculty positions in clinical infectious diseases at Cornell Medical College and U.C.L.A. School of Medicine. During his pharmaceutic career Dr Brown has had leadership roles in clinical trial programs that resulted in global product registrations for AZT for children with HIV, lamivudine and telbivudine for patients with hepatitis B, lymphoblastoid interferon for hepatitis C, and atovaquone for pneumocystis pneumonia. Dr. Brown studied Molecular Biophysics and Biochemistry at Yale University and received his M.D. degree from Georgetown University School of Medicine, where he was elected to Alpha Omega Alpha, the national medical honor society. He completed clinical specialty training at The New York Hospital-Cornell Medical Center and post-doctoral training in infectious diseases and virology at Yale University School of Medicine. He has authored over 180 scientific publications and he has received leadership awards from the Hepatitis B Foundation and the American Liver Foundation. During the past 20 years Dr Brown has served in various advisory roles to pharmaceutic and biotech companies, foundations, and government agencies (NIH and FDA).